Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is its cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. We show 36 historical shares outstanding datapoints in our MRSN shares outstanding history coverage, used to compute MRSN market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing MRSN market cap history over the course of time is important for investors
interested in comparing MRSN's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of MRSN versus a peer is one thing; comparing
MRSN market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like MRSN can fluctuate over the course of history.
With this page we aim to empower investors researching MRSN by allowing them to research the MRSN market cap history. |
Free MRSN Email Alerts:
Video: The Importance of Market Cap
